Gene therapy for ischemic heart disease: review of clinical trials

Terapia gênica para cardiopatia isquêmica: revisão de ensaios clínicos

Bruna Eibel¹, Clarissa G. Rodrigues², Iamarilde I. Giusti¹, Ivo A. Nesralla³, Paulo R. L. Prates³, Roberto T. Sant’Anna⁴, Nance B. Nardi⁵, Renato A. K. Kalil⁶

Abstract

Severe ischemic heart disease with refractory angina, occurs in increasing incidence. Alternative forms of treatment, in an attempt to reduce myocardial ischemia and relief of symptoms has been studied. In this context, gene therapy is an option, for the possibility of inducing angiogenesis, establish collateral circulation and reperfuse ischemic myocardium. Several clinical trials have been conducted and, except for specific cases of adverse effects, there is indication of safety, feasibility and potential effectiveness of therapy. The clinical benefit, however, is not yet well established. In this article we review the clinical trials of gene therapy for patients with ischemic heart disease. The approach includes: (1) myocardial ischemia and angiogenesis on the pathophysiological aspects involved, (2) growth factors, dealing with specific aspects and justifying the use in cardiac patients with no option for conventional therapy, (3) controlled clinical trials, where a summary of the main studies involving gene therapy for severe ischemic heart disease is presented, (4) our experience, especially on preliminary results of the first gene therapy clinical trial in Brazil and (5) future prospects.

Keywords: Gene therapy. Myocardial ischemia. Angina pectoris.

Resumo

Cardiopatia isquêmica grave com angina refratária a formas convencionais de tratamento apresenta-se em uma crescente incidência. Para tratar angina refratária, terapias alternativas na tentativa de redução da isquemia miocárdica e alívio de sintomas têm sido estudadas. Neste contexto, a terapia gênica representa uma opção, pela possibilidade de induzir angiogênese, estabelecer circulação colateral e reperfundir miocárdio isquêmico. Diversos ensaios clínicos têm sido conduzidos e, com exceção de casos isolados e específicos de efeitos adversos, há indicação de segurança, viabilidade e potencial eficácia da terapia. O benefício clínico não está bem definido. Neste artigo, revisamos os ensaios clínicos que utilizaram terapia gênica para tratamento de pacientes cardiopatas isquêmicos. A abordagem inclui: (1) isquemia miocárdica e angiogênese, sobre os aspectos fisiopatológicos envolvidos; (2) fatores de crescimento, tratando sobre aspectos específicos e justificando a utilização em pacientes cardiopatas isquêmicos sem opções pela terapêutica convencional; (3) ensaios clínicos controlados, onde é apresentado um resumo dos principais estudos envolvendo terapia gênica para tratamento da cardiopatia isquêmica grave; (4) nossa experiência, especialmente sobre resultados preliminares do primeiro ensaio clínico de terapia gênica do Brasil e (5) perspectivas.


1. Master’s Degree of the Postgraduation Program of the Cardiology Institute of Rio Grande do Sul/University Foundation of Cardiology (IC/FUC), Porto Alegre, RS, Brazil.
2. PhD Student of the Postgraduation Program of IC/FUC, Porto Alegre, RS, Brazil.
3. Cardiac Surgeon of IC/FUC, Porto Alegre, RS, Brazil.
4. Cardiologist of IC/FUC, Porto Alegre, RS, Brazil.
5. Biologist and Collaborator Researcher of IC/FUC, Porto Alegre, RS, Brazil.
6. PhD; Institute of Cardiology of Rio Grande do Sul/University Foundation of Cardiology (IC/FUC) and Federal University of Health Sciences of Porto Alegre (UFSCPA), Porto Alegre, RS, Brazil.

This study was carried out at Cardiology Institute of Rio Grande do Sul/ University Foundation of Cardiology (IC/FUC) and Federal University of Health Sciences of Porto Alegre (UFSCPA), Porto Alegre, RS, Brazil.

Correspondence address:
Renato A. K. Kalil
Av. Princesa Isabel, 370 – Santana – Porto Alegre, RS, Brazil – Zip Code: 90620-000 - E-mail: kalil.pesquisa@cardiologia.org.br

Article received on June 14th, 2011
Article accepted on September 5th, 2011
INTRODUCTION

It is estimated that cardiovascular disease (CVD) cause approximately 17 million deaths worldwide each year, with higher prevalence in developed countries [1]. CVD should be leaders in mortality in the developing world within the next decades, reaching epidemic levels [1]. Coronary artery disease (CAD) is a problem of increasing prevalence, especially in large cities and the populations of older age, its mortality is 80% of deaths from CVD [2,3]. Angina refractory to traditional forms of treatment in cardiology, including percutaneous and surgical revascularization and optimal drug therapy, represents up to 15% of all cases of angina [2]. According to statistics from the American Heart Association [3], the prevalence of refractory angina in the U.S. population is 4.6%, affecting 58% of patients with CAD and growing rapidly with increasing age. Despite advances in treatment modalities, it is estimated that the incidence of patients with refractory angina will increase in coming years [4,5], pointing to the need for new treatment options.

In this context, gene therapy could be an option, due to the potential to induce myocardial angiogenesis and establish collateral circulation [5]. Gene therapy can be defined as a set of techniques that allow the insertion and expression of a therapeutic gene in target cells that have some kind of disorder of genetic origin (not necessarily hereditary), enabling the correction of inappropriate gene products that cause diseases, therefore being an alternative for the treatment of diseases based on the transfer of genetic material [6-8]. Studies have tested the effects on ischemic heart disease patients using different growth factors, several doses, vectors and routes of administration. It can be emphasized the vascular endothelial growth factor (VEGF), a regulator of endothelial cells, which has the property of mediating angiogenesis during tissue repair [4].

The availability of vectors with tropism for the myocardium, capable of a long and stable protein expression [9], and the isolation of progenitor cells with regenerative and angiogenic potential [10] offers possibilities for development of therapy based on protection and regeneration of ischemic myocardium.

Although promising, the clinical effects on the myocardial vasculature provided by gene therapy remain to be clarified fully. The aim of this study is to review the clinical trials of gene therapy for the treatment of ischemic heart disease patients.

GENE THERAPY APPLIED TO ISCHEMIC CARDIOMYOPATHY

Myocardial Ischemia and Angiogenesis

In the pathophysiology of ischemic heart disease, two processes are involved: supply and demand of myocardial oxygen. Myocardial ischemia occurs when there is imbalance between supply and demand for oxygen. Two situations alter the oxygen supply to the myocardium, ischemia and hypoxia. In some conditions, the impairment of oxygen is secondary to decreased blood flow and in other situations, the increase in oxygen demand is the main responsible for myocardial ischemia [11].

Features of molecular biology and gene therapy have been developed for application in cardiovascular therapy, in situations where there are no options, or when these conventional methods have limitations. The main area of development of gene therapy in cardiology is the induction of myocardial angiogenesis with potential benefits in end-stage ischemic heart disease, after exhaustion of pharmacological, surgical and interventional resources using catheter, ie, in those refractory cases to all forms of treatment, where only the use of cardiac transplantation would be possible [4].

Angiogenesis, the formation of new vessels from existing endothelium of blood vessels, has an important role in embryonic development, tissue repair and progression of a variety of pathological processes [12,13]. Angiogenesis induced by administration of growth factors is intended to promote the formation of new blood vessels, capillaries and arterioles.

The mechanism of angiogenesis can be initiated by factors of a mechanical nature, by inflammatory or hypoxic process (energy imbalance). The process of angiogenesis occurs in stages (Figure 1) comprising: vessel dilation, endothelial cell activation, platelet activation, secretion of plasminogen activators and proteolytic enzymes, mast cell degranulation, activation of macrophages, disruption of the basement membrane and increased permeability with release of fibrin and other proteins. Following, formation of pseudopodia occurs, degradation of extracellular matrix, migration of endothelial cells to the extravascular space with the same proliferation and formation of shoots of vascular tissue. Finally, they form new basement membrane and maturation of the new establishment of the vascular wall to blood flow, formation of tubes and connections, establishing new vessels [14].

The idea that angiogenic factors may promote revascularization of ischemic tissues is called therapeutic angiogenesis [15]. The concept of therapeutic angiogenesis in humans through clinical trials phase I went ahead with the idea of testing this strategy in ischemic cardiomyopathy. Therefore, therapeutic angiogenesis is a strategy designed to amplify the natural process of angiogenesis and reperfuse ischemic tissues, which may represent a new process of revascularization in these high-risk patients [16].

There is a direct influence of inflammation and hypoxia on angiogenesis. Inflammation increases the production
of PR-39 macrophage-derived peptide, this inhibits the degradation of HIF-1α (hypoxia-inducible factor 1-α) leading to increased expression of VEGF and its receptors [17]. Inflammation induces the production of cytokines that promote angiogenesis [18]. In contrast, PR-39 increases the production of fibroblast growth factors (FGF), which have angiogenic power. Mechanical factors may act by activating the same mechanism, resulting in angiogenesis [10].


The formation of new blood vessels responds to the stimulation of angiogenic factors, which regulate endothelial migration, proliferation, survival, and proteolytic activity. Among the factors described in the literature, VEGF has emerged as a critical regulator of pro-angiogenic process [19-21]. This molecule promotes the formation of new vessels and their morphogenesis, through a complex process of angioregulatory events [22,23].

VEGF, family member of VEGF A, which consists of five isoforms resulting from alternative divisions of a single gene, ie, VEGF121, VEGF145, VEGF165, VEGF189 and VEGF206, is a growth factor specific to the endothelium [24,25]. It acts mainly by activating two Flt-1 tyrosine kinase receptors (fms-like tyrosine kinase-1, VEGF receptor-1) [26] and KDR (kinase-insert domain-containing receptor, VEGF receptor-2) [27] but can also activate other receptors, such as Neuropilins-1 and 2 [28]. VEGF may represent a new treatment modality for ischemic heart disease. This is due to the possibility of developing new blood vessels or promote the reformation of existing vessels [29]. The VEGF165 contains 165 amino acids and works by interacting with specific receptors on endothelial cells, initiating the cascade of events that culminates in endothelial cell migration, proliferation and aggregation of microtubules that will eventually form a network of arterial and venous systems.

Gene therapy in cardiovascular diseases is not intended

![Fig. 1 - Sequence of events in the angiogenesis process [30]](image-url)
to replace an abnormal gene, but supraregular the expression of a useful protein, increasing DNA content. Its effectiveness depends on the gene vector and method of administration used [30]. VEGF functions both as an important marker of endothelial damage, as the mediator of repair. In cases of injury such as ischemia, inflammation and infarction have their expression increased. In addition, it encourages the maintenance, mobilization and recruitment of endothelial progenitor cells (EPC) from bone marrow [31]. The angiogenic potential of VEGF stimulates endothelial production of nitric oxide through activation of nitric oxide synthase (eNOS) (Figure 2).

The endothelium synthesizes important substances, playing a key role on the vascular control, both in physiological conditions and in pathological processes such as acute coronary syndromes. The monolayer of endothelial cells acts as a nonstick surface for platelets and leukocytes, producing a variety of important regulatory factors, such as NO [32]. Thus, influences not only vascular tone but also its remodeling through the production of substances promoting and inhibiting their growth [33].

Dysfunction in endothelial cells leads to a loss of antithrombotic properties of vascular wall and corresponds to the beginning of the atherosclerotic process [32]. The reconstruction occurs by endothelial migration and proliferation of circulating mature endothelial cells.

Stage 0 of angiogenesis, stable vessel. Major components of a normal capillary that can be involved in the process of angiogenesis.

Stage 1 of angiogenesis: changes within the vessels.

Stage 2 of angiogenesis: formation of a new channel.

Stage 3 of angiogenesis: maturation of the new vessel.

Fig. 2 - Mobilization of endothelial progenitor cells for neovascularization. Adapted from Murasawa et al. [68]
However, these cells have low proliferative potential and their ability to repair is limited. Evidence indicates that peripheral blood contains bone marrow cell subsets, with properties similar to embryonic angioblastic. EPCs have a proliferative capacity and differentiate into mature endothelial cells, and can be induced by various cytokines or growth factors, acquiring different phenotypes [32].

The FGF family comprises at least nine polypeptides, including acidic FGF and basic FGF. Unlike VEGF, FGF acts in the mitogenesis of endothelial cells, fibroblasts and smooth muscle cells [18]. The increased availability of FGF provided the use of this gene has been most studied. Among the experimental studies, we highlight the report by Kawasuji et al. [34] in a model of acute myocardial infarction, where the response to FGF demonstrated to increase the number of capillaries in the border zone and in the epicardium of the infarcted area, the increased blood flow in these areas and the improvement in left ventricular ejection fraction 7 days after infarction.

On the other hand, HGF is a potent mitogen for a wide variety of cells, and angiogenic, antiapoptotic and possess antifibrotic properties [35,36]. In a pilot study of gene therapy in patients with CAD, Yang et al. [37] reported the growing evidence of the beneficial effects of HGF in myocardial infarction, heart failure and peripheral arterial disease. The aim of this study was to assess the effects of intracoronary administration of an adenovirus vector encoding the human HGF gene (Ad-HGF) on serum levels of cytokines and mobilization of CD34 (+) and CD117 (+) cells in patients with heart disease. Given the findings, it was concluded that gene therapy with HGF may play an important role in the regulation of inflammatory cytokines and induce mobilization of EPCs in patients with CAD.

Genetic vectors are all DNA molecules with potential for autonomic replication within the host cell in which DNA sequences can be inserted and expanded. The origin of the vector plasmid allows to classify in bacteriophage or viral infections [38]. They are used to transport genes into recipient cells. They have not only markers for ease of recognition as well as replicating sequences. Common vectors include plasmids carriers for transportation of naked DNA and viral vectors such as adenovirus, retrovirus and lentivirus.

Advantages and disadvantages compared to the vector used include the size of the inserted gene, the site of incorporation in the nucleus, the duration of expression, the transfer efficiency and the degree of body’s immune response [39]. The plasmid vector is expressed by only a few days after viral vector administration and shows gene expression for several weeks [40]. Thus, the clinical studies that attempt to treat end-stage ischemic disease through gene therapy may be limited by duration of exposure to inadequate angiogenic agent [4].

Gene therapy suffered a major setback when the occurrence of death in a research subject, probably due to high viral load administered, and there was cancellation of several clinical projects and return to the laboratory research. Since 2000, few projects have been developed for clinical application. Theoretically, before being introduced into the patient, the viruses used as vectors suffer from several genetic changes, so that the therapeutic gene is inserted, while several other genes that confer virulence are removed or inactivated [7,41,42]. Thus, when binding and invading the target cell, the viral vectors inject its genetic material containing the therapeutic gene in the patient’s DNA, allowing transcription and translation of the gene to their corresponding functional protein, or using the molecular machinery of the host cell to express their genes. However, in specific cases, the virulence became something uncontrollable, where the therapy became the cause of death of patients undergoing such intervention. On the other hand, plasmid vectors have no gene size limit to be inserted and induces minimal immune response, resulting in sustained transgenic expression. The disadvantage is the low rate of transfer of the encoding gene of the angiogenic factor [43].

The ideal vector would be one that combines low immunogenicity and a satisfactory safety profile, with high efficiency of transfection and transgene expression to specific time periods [4].

Gene transfer to the myocardium has been used as an alternative strategy to achieve a sustained local expression of angiogenic proteins [44]. There is a variety of different methods to replace or repair the genes targeted in gene therapy. A normal gene can be inserted into a nonspecific location within the genome to replace a nonfunctional gene, which is the most common approach, though, an abnormal gene could be replaced by a normal gene through homologous recombination, an abnormal gene could be repaired through selective reverse mutation, which returns the gene to its normal functions and also the regulation of a gene can be altered, such regulation corresponding to the degree to which a gene is active or inactive [6-8].

**Controlled Clinical Trials of Gene Therapy**

Despite more than a decade of achievement of the first clinical trial of gene therapy [45], the real clinical benefits of this therapy still need to be better elucidated. Research has attempted to identify other parameters and outcomes that can provide objective evidence of bioactivity and clinical improvement [4]. Thus, among the studies, it can be observed the use of different genes, doses, types of vectors and routes of administration. In Table 1, are gathered clinical trials involving gene therapy with VEGF with interventions performed via left minithoracotomy, in Table 2, studies using the percutaneous method, and in Table 3 are gathered clinical trials of gene therapy with FGF.
Table 1. Clinical trials involving gene therapy with intramyocardial VEGF by left mini-thoracotomy.

<table>
<thead>
<tr>
<th>Author and Year</th>
<th>Vector</th>
<th>Patients</th>
<th>Outcomes</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Losordo et al. [45], 1998</td>
<td>VEGF\textsubscript{165}</td>
<td>5 patients; CAD, refractory angina, underperfused myocardial areas, but viable AC (3/4)</td>
<td>Myocardial perfusion and symptoms of disease in 60 days</td>
<td>Reduction in angina between 10 and 30 days after treatment, reducing the consumption of nitrate in 60 days ($P &lt; 0.05$), no reduction of myocardial ischemia in 60 days</td>
</tr>
<tr>
<td>Symes et al. [48], 1999</td>
<td>VEGF\textsubscript{165}</td>
<td>125 i g/n=10, 250 i g/n=10; CAD, refractory angina, reversible ischemia, AC (3/4)</td>
<td>Safety of the therapy and myocardial perfusion in 180 days</td>
<td>Safety and feasibility of therapy, improvement of myocardial perfusion in 60 days, SSS = 19.4 ± 3.7 versus 15.9 ± 3.4, $P = 0.025$</td>
</tr>
<tr>
<td>Vale et al. [49], 2000</td>
<td>VEGF\textsubscript{165}</td>
<td>13 patients; CAD, refractory angina, myocardial areas underperfused but viable, AC (3/4)</td>
<td>Myocardial perfusion and left ventricular performance</td>
<td>Reduction of ischemia before (15.26 ± 0.98%) versus after (9.94 ± 1.53%, $P = 0.004$) therapy, improvement of myocardial function</td>
</tr>
<tr>
<td>Reilly et al. [50], 2005</td>
<td>VEGF\textsubscript{2}</td>
<td>30 patients; CAD, AC (3/4) with no revascularization options;</td>
<td>Safety and adverse events at 1 year of therapy</td>
<td>After 1 year, 3 (11.5%) patients had AC 3 and 23 (88.5%) AC 1 or 2, there were 4 deaths (13.8%), MI 5 (17.2%) 7 CABG (24.1%), 15 hospitalizations and two new cancer diagnoses</td>
</tr>
<tr>
<td>REVASCStewart et al. [51], 2006</td>
<td>Adenoviral VEGF\textsubscript{121}</td>
<td>Active/placebo group (32/35), CAD not eligible for revascularization, refractory angina, AC (2/4)</td>
<td>Time on ergometric test and ST segment depression in 1 mm in diameter at 26 weeks</td>
<td>Time on ergometric test at 1 mm ST segment depression was significantly higher in VEGF\textsubscript{121}-ad ($P = 0.026$); AC improved in the group ad-VEGF121($P &lt; 0.001$)</td>
</tr>
<tr>
<td>Ruel et al. [52], 2008</td>
<td>Plasmid VEGF\textsubscript{165} and supplemental oral L-arginine associated with CABG.</td>
<td>VEGF/L-arg (5),Placebo/L-arg (6),VEGF/placebo (7),Placebo/placebo (1);CAD with commitment of the ADA</td>
<td>Myocardial perfusion, left ventricular contractility and AC in 3 months</td>
<td>Group VEGF/L-arg showed improvement in perfusion and contractility of the anterior myocardial wall ($P = 0.02$)</td>
</tr>
<tr>
<td>Kalil et al. [53], 2010</td>
<td>plasmid VEGF\textsubscript{165}</td>
<td>13 patients, ischemic heart disease, LV ejection fraction greater than 25%;symptoms of angina and/or IC, myocardial hypoperfusion</td>
<td>Myocardial perfusion, ergometric test time, quality of life, CF according to NYHA in 3 months</td>
<td>Improvement of myocardial perfusion SSS (18.38 ± 7.51 versus 15.31 ± 7.29, $P = 0.003$) and SRS (11.92 ± 7.49 versus 8.53 ± 6.68, $P = 0.002$); trend towards improvement in ergometric test time (7.66 ± 4.47 versus 10.29 ± 4.36, $P = 0.08$), improved quality of life, second IC accordingNYHA class and AC.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Author and year</th>
<th>Vector</th>
<th>Patients</th>
<th>Outcomes</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vale et al. [54], 2001</td>
<td>Intramyocardial of VEGF, guided by electromechanical mapping (NOGA)</td>
<td>6 patients, angina refractory to therapy of CAD, reversible ischemia, AC(3/4)</td>
<td>Myocardial perfusion, time during ergometric testing, angina episodes in 360 days</td>
<td>Reduction of episodes of angina, improvement in ergometric test performance from 7 to 127 seconds (72 ± 25 s), improvement in myocardial perfusion at rest and stress</td>
</tr>
<tr>
<td>Losordo et al. [25], 2002</td>
<td>Intramyocardial administration via electromechanical mapping of plasmid VEGF&lt;sub&gt;165&lt;/sub&gt; and after percutaneous coronary intervention</td>
<td>Group active/placebo (12/7), CAD not eligible for revascularization, refractory angina, AC(3/4)</td>
<td>Change in AC and exercise tolerance in 12 weeks</td>
<td>Improvement in AC - VEGF&lt;sub&gt;2&lt;/sub&gt; group versus placebo (-1.3 versus -0.1, P = 0.04), exercise tolerance (91.8 versus 3.9 seconds)</td>
</tr>
<tr>
<td>Hedman et al. [28], 2003</td>
<td>Intracoronary administration of adenoviral plasmid VEGF&lt;sub&gt;165&lt;/sub&gt; and after percutaneous coronary intervention</td>
<td>VEGF-ad (37), VEGF-P (28), Placebo (38); CAD, AC (2/3), percutaneous coronary intervention</td>
<td>% minimal luminal diameter stenosis in coronary angiography at 6 months</td>
<td>Clinical restenosis rate: 6%, minimum diameter and percent stenosis were not different between groups, myocardial perfusion showed a significant improvement in the VEGF-ad group</td>
</tr>
<tr>
<td>VIVA Trial</td>
<td>Intracoronary infusion, followed by intravenous infusion of VEGF</td>
<td>VEGF - high dose (59), VEGF - low dose (56), placebo (63); refractory angina, underperfused myocardium, but viable</td>
<td>Myocardial perfusion time during exercise testing, AC and quality of life in 120 days</td>
<td>There was no significant improvement in myocardial perfusion, increase in performance under exercise test (high dose versus placebo: 48 versus 23 seconds, P = 0.15), reduction of angina episodes and improved quality of life</td>
</tr>
<tr>
<td>Kastrup et al. [55], 2005</td>
<td>Percutaneous intramyocardial administration via electromechanical mapping of plasmid VEGF&lt;sub&gt;165&lt;/sub&gt;</td>
<td>Group active/placebo (40/40), coronary artery disease not eligible for revascularization, refractory angina, AC(3/4)</td>
<td>Myocardial perfusion, wall motion mapping by NOGA, left ventriculography and AC in 3 months</td>
<td>Myocardial perfusion was not different between the VEGF&lt;sub&gt;165&lt;/sub&gt; and placebo group (38 ± 3%, 44 ± 2%), wall motion by NOGA (P = 0.04) and left ventriculography (P = 0.03) improved compared to placebo; improvement in AC with no difference between</td>
</tr>
<tr>
<td>Ripa et al. [56], 2006</td>
<td>Percutaneous intramyocardial administration of VEGF&lt;sub&gt;165&lt;/sub&gt; using electromechanical mapping and subcutaneous injection of G-CSF</td>
<td>VEGF&lt;sub&gt;165&lt;/sub&gt; + G-CSF (16), VEGF&lt;sub&gt;165&lt;/sub&gt; (16), Placebo (16); coronary artery disease not eligible for revascularization, refractory angina, AC(3/4)</td>
<td>Change of perfusion defects, measured by SPECT in 3 months</td>
<td>There was no improvement in myocardial perfusion in both treated groups and clinical symptoms have not changed</td>
</tr>
<tr>
<td>Stewart et al. [57], 2009</td>
<td>Administration of Plasmid VEGF&lt;sub&gt;165&lt;/sub&gt; by endocardial catheter through the NOGA electroanatomic catheter</td>
<td>A multicenter study: group active/placebo (48/45), advanced coronary artery disease, AC (3/4)</td>
<td>Myocardial perfusion, time in ergometric time and AC at 6 months</td>
<td>There was no improvement in myocardial perfusion; significant reduction in the ischemic area in both groups, increase in exercise test time and improvement in AC</td>
</tr>
</tbody>
</table>

**Table 2.** Clinical trials involving gene therapy with VEGF percutaneously.

**VEGF:** Factor Vascular Endothelial Growth; **AC:** Angina Class, **Ad:** adenoviral; **P:** Placebo, **AMI:** acute myocardial infarction, **G-CSF:** colony-stimulating factor Granulocyte; **LV:** left ventricle, **CI:** Heart Failure ; **NYHA:** New York Heart Association; **SSS:** Stress score addition, **SRS:** Score addition of Rest

**Rev Bras Cir Cardiovasc 2011;26(4):635-46**

Eibel B, et al. - Gene therapy for ischemic heart disease: review of clinical trials
This study highlights the potential clinical applications of growth factors in humans, since experimental studies have shown favorable results and initial clinical studies in humans do not report adverse events related. Current tests report that the use of high doses of VEGF, compared with low doses and placebo, improves myocardial perfusion in patients with severe angina and provides evidence of a dose-dependent positive effect [46,47]. Confronted with evidence, VEGF has been shown to be a potential angiogenic factor, which benefits in medium and long term follow-up have been or are being assessed, including the improvement of quality of life, functional class of heart failure, angina class, functional capacity and reduction of myocardial ischemia [25,28,45,46,48-57].

FGF [58-60] and HGF [61] have also been demonstrating its potential benefits in the induction of myocardial angiogenesis, and to further develop this promising therapeutic approach we must critically assess the results and the experimental protocols, to identify factors that may have undermined the effectiveness of therapy or confounding data interpretation [4].

As the route of administration, the intramyocardial route proved to be more effective and, therefore, have been the most widely used in studies involving gene therapy in cardiology [38]. Previous studies suggest that administration by intramuscular injection offers the possibility to offer more effective in focal areas of ischemic muscle [4].

There are questions concerning the safe transfer of angiogenic factors, and also in relation to time of expression [4,62], where it is known that plasmids carriers of angiogenic factors protein, because they have more short expression and do not incorporate DNA to which the cell will connect to, have a lower risk of this adverse effect. Since the viral vectors require care in biosafety, it is unnecessary measure with non-viral vectors. Studies indicate temporary events related to use of adenovirus, such as fever or elevated serum C-reactive protein, liver enzymes and antibody titration [22]. Hao et al. [63] published in 2007, an experimental study on myocardial angiogenesis VEGF165 compared with adenoviral plasmid vector. These authors demonstrated equivalent benefits in terms of ventricular

---

Table 3. Clinical trials involving gene therapy with FGF.

<table>
<thead>
<tr>
<th>Author and Year</th>
<th>Vector</th>
<th>Patients</th>
<th>Outcomes</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>FGFAGENTSGrines et al. [58], 2002</td>
<td>Administration of Ad5-FGF4 by intracoronary via</td>
<td>Group active/placebo (60/19), coronary artery disease, AC (2/3)</td>
<td>Safety and time of exercise testing in 12 weeks</td>
<td>Single administration of Ad5-FGF4 was safe and well tolerated; Ad5-FGF4 group showed improvement in the time of exercise testing in subgroup analysis (1.6 versus 0.6 minutes, P = 0.01, n=50)</td>
</tr>
<tr>
<td>2 Grines et al. [59], 2003</td>
<td>Administration of Ad5-FGF4 by intracoronary via</td>
<td>Group active/placebo (35/17), coronary artery disease, not eligible for revascularization, refractory angina, AC (2/4)</td>
<td>Change of perfusion defects, measured by adenosine SPECT in 8 weeks, follow-up of 12 months</td>
<td>Ad5-FGF4 resulted in a significant reduction of ischemia (4.2% absolute, 21%, P &lt;0.001), while placebo did not improve (P = 0.32)</td>
</tr>
<tr>
<td>AMENT-3</td>
<td>Administration of Ad5-FGF4 by intracoronary via</td>
<td>High dose (175), Low-dose (180), Placebo (177), coronary artery disease and refractory angina, AC (2/4); 3 AGENT: no immediate need for revascularization AGENT 4: not eligible for revascularization</td>
<td>Change in time of exercise testing in 12 weeks, follow-up of 12 months</td>
<td>Significant beneficial effect of gender, women showed improvement in exercise test time and improvement of AC</td>
</tr>
</tbody>
</table>

FGF: fibroblast growth factor; AC: Class of Angina
function \((P<0.05)\) for plasmids and adenovirus after 4 weeks, however, in this study, the TUNEL technique that detects DNA breaks that occur during the process of apoptosis, demonstrated an increase in frequency of cardiomyocyte apoptosis in adenovirus group \((P<0.02)\).

Almost all clinical trials of gene therapy and study population are patients with end stage ischemic disease, since the possible increased risk in relation to the benefits associated with new treatments are acceptable and can be used as an adjunct to conventional therapy. However, in very advanced clinical situations, therapy may not lead to an improvement of great intensity and measurable by available methods, even when treatment shows some clinical benefit \([4.64]\).

**Local Experience**

In the Cardiology Institute of RS/FUC and the Discipline of Cardiology of UFCSPA, in collaboration with the Laboratory of Immunogenetics, UFRGS, we previously developed experimental studies \([65-67]\) and recently performed the first gene therapy clinical trial in Brazil, using VEGF165 for refractory angina \([53]\).

In experimental studies, we used a canine model of myocardial infarction in acute and chronic phases in an attempt to assess the processes of gene therapy. Recently, we developed a controlled clinical trial, phase I/II (ClinicalTrialNCT00744315) \([53]\) in order to clinically assess the effects of gene therapy with VEGF165 in patients with advanced coronary artery disease (CAD), not eligible for revascularization or percutaneous surgical. The thirteen patients received optimal drug therapy for at least six months and underwent administration of intramyocardial injections of 2000 µg of plasmid VEGF165. Patients were assessed by myocardial scintigraphy, exercise testing, quality of life questionnaire (Minnesota) and determination of classes of heart failure (NYHA) and angina (CCS). In partial results of 3 months of evolution, it was concluded that the therapy proved to be safe and feasible, tending to improvement in severity of angina and reducing the intensity of myocardial ischemia.

**CONCLUSIONS**

Over 1,000 patients were enrolled in controlled clinical trials of gene therapy, covering more than a decade and so far, except for specific cases, no adverse safety signal was detected, indicating that the therapy is safe, feasible and potentially effective although they have not produced conclusive evidence of its benefits definitely. Reports of retinopathy, cancer or other diseases that could be driven by vascular growth were perceived as equally distributed in treated and placebo groups in randomized clinical trials.

More definite conclusions about risks and complications will require more follow-up time and number of patients undergoing therapy \([4]\). Thus, gene therapy has emerged as a potentially beneficial alternative to ischemic heart disease patients, when conventional therapies are exhausted. The definition of angiogenic success, for better assessment of the results needs to be rethought and defined by methods of higher sensitivity and specificity.

Traditionally, therapy for the treatment of cardiovascular disease should demonstrate improvements in morbidity and mortality. However, for this patient population, the fact of improving quality of life, and decrease or elimination of episodes of angina and reduction of events of hospitalization may be considered the biggest gains on this new therapy. Knowing that the manifestations of cardiovascular disease is progressive, the main aim is to offer patients significant decrease of symptoms and delay this progression.

The future directions of gene therapy indicate probable combinations of angiogenic factors or individual factors (HIF 1-α) that activate different pathways of neovascularization. Combinations of cell therapy and angiogenic factors, as well as the use of biomaterials to improve the microenvironment are other promising strategies for ischemic tissue repair \([4]\).

**ACKNOWLEDGEMENTS**

The authors acknowledge the participation in group projects of Gene Therapy of the Institute of Cardiology of Rio Grande do Sul/University Foundation of Cardiology, toe following colleagues: Leonardo Karam Teixeira, Felipe Borsu de Salles, Ana Paula Furlani, Eduardo Mastalir, Paulo Lavaníere Moreno, Sang Won Han, Eduardo Ludwig, Gabriel Grossman, João Ricardo Michielin Sant’Anna, Guaracy Fernandes Teixeira Filho, Melissa Medeiros Markoski, Andrés Delgado Cañedo, Melissa Camassola, Iran Castro, Maria Claudia Irigoyen, Luiza Macedo Braga and Rogério Sarmento Leite.

**REFERENCES**


49. Vale PR, Losordo DW, Milliken CE, Maysky M, Esakof DD, Symes JF, et al. Left ventricular electromechanical mapping to assess efficacy of phVEGF(165) gene transfer for therapeutic


